On April 16, 2024, WLF filed an amicus brief in an important case about States’ inability to amend federal law. An Eighth Circuit panel held that Arkansas could amend the federal statute regulating the 340B Program. WLF’s brief asks the full Eighth Circuit to rehear the case. As the brief explains, the 340B Program is so large that any decision whether to expand the program must be made at the national level by Congress. WLF’s brief also explains the consequences of allowing the panel’s decision to stand. It will lead to less research and development by pharmaceutical companies, meaning fewer life-saving drugs. It will also increase regulatory costs leading to higher prices for patients.
Documents: